Categories Earnings, Health Care

Moderna impresses on the financial side as well in Q2

Gets $400 million in customer deposits for the potential supply of its vaccine across the world

Moderna, Inc., (Nasdaq: MRNA), a prime contender in Covid-19 vaccine research, on Wednesday, reported second-quarter financial results that smashed past analysts’ estimates. The company’s revenues during the second quarter came in at $66.3 million, more than double of what the street had anticipated.

Q2 net loss narrowed to 31 cents per share, compared to 41 cents per share a year ago. Analysts had quoted a net loss of 35 cents per share.   

Moderna shares rose 1.5% immediately following the announcement. MRNA stock is one of the top performers this year, rising 310% since January.

Moderna Inc earnings Q2.

Looking forward to listening to management/ analyst comments on Q2 results? Stay tuned here for Moderna Q2 2020 earnings call transcript

Moderna said it has received about $400 million in customer deposits for the potential supply of its Phase 3 Covid-19 vaccine mRNA-1273.

CEO Stéphane Bancel said, “As we pivot to a commercial-stage company, we recognize the need for responsible pricing in the face of the pandemic. We look forward to continuing our progress as we prepare for the Phase 3 readout and the expected subsequent filing of our BLA.”

Enrollment is ongoing for the Phase 3 COVE study.

Last month, the company had provided Phase 1 interim results, besides announcing the start of Phase 3 trials on July 27.  

Also Read:  Moderna Inc  (NASDAQ: MRNA) Moderna Vaccine Against COVID-19 Phase 1 Interim Results Publication Call Transcript

____

Most Popular

Highlights of Aurora Cannabis (ACB) Q4 2020 earnings report

Aurora Cannabis, Inc. (NYSE: ACB) reported a wider loss for the fourth quarter of 2020, hurt by a 5% decrease in revenues. The company’s stock fell sharply during Tuesday’s after-hours

Infographic: Stitch Fix Q4 2020 earnings

Stitch Fix (NASDAQ: SFIX) reported fourth-quarter 2020 financial results after the closing bell on Tuesday. The company reported an 11% increase in Q4 revenues to $443.4 million, beating Wall Street

Nike Inc. (NKE) stock spikes after beating Q1 2021 estimates

Nike Inc.'s (NYSE: NKE) profit and revenue in the first quarter of fiscal 2021 surpassed the market's estimates and sent the NKE stock up by about 7% in the extended

Top